Alex Philippidis Senior News Editor Genetic Engineering & Biotechnology News
Manufacturing Grows Along with the Development of Biologics
The market for bioprocess technology is growing with the rise and development of biologics: A study last year by Research and Markets projected that market to zoom from $39.3 billion in 2016 to $71.03 billion by 2021, based on a compound annual growth rate (CAGR) of 12.4% over the five-year period.
The report listed as reasons overall biopharma industry growth, increases in R&D spending, rising demand for vaccine production, and technological advancements.
Below is a list of 15 top bioprocessing companies, ranked by revenue—either companywide for companies entirely focused on the segment, or for business segments focused on biologics manufacturing in the case of companies with broader operations. Each company is listed by name, 2017 revenues, and a short explanation of where the revenues were derived.
#15. Solesis Medical (Fenner PLC)
2017 revenues: £59 million ($82.088 million)
Figure includes total medical revenue revenues for the year ending August 31, 2017. Nearly all of that (£55 million) was generated by Fenner’s Solesis Medical unit, which includes Charter Medical (single-use products for blood management, bio-processing and cell therapy) as well as Secant Group (biomedical textile components and biomaterials). Fenner does not disclose how much of its revenue relates to bioprocessing.
2016-2017 revenues: $125.015 million
Figure combines $99.516 million reported for the first three quarters of 2017 with $25.499 million reported for Q4 2016. The company at deadline had not announced a date for reporting full-year 2017 results. During a presentation at the J.P. Morgan 36th Annual Healthcare Conference on January 9, Repligen President and CEO Tony J. Hunt said 2017 revenues would range between $139 million and $142 million.
2017 revenues: €673.9 million ($834.727 million)
Figure includes the first half of 2017 and second half of 2016; the company at deadline had not announced a date for reporting full-year 2017 results. Last year the company reported 2016 results on April 28. “We are assuming that our business will continue to develop positively overall for the whole year 2017 and we expect growth to be higher than the industry average,” Thomas Bachmann, Eppendorf’s president & CEO, said August 11 in a statement.
2017 revenues: $879 million
Figure consists of company’s Life Sciences segment, whose products “include general labware and equipment, as well as specialty surfaces, media, and reagents that are used for cell culture research, bioprocessing, genomics, drug discovery, microbiology, and chemistry 2018.” Corning has projected that Life Sciences sales are expected to grow by a mid-single-digit percentage.
#11. Boehringer Ingelheim
2016 revenues: €776 million ($951.1 million)
Boehringer Ingelheim reports revenues annually; the company at deadline had not announced a date for reporting full-year 2017 results. Last year the company reported 2016 results on April 5. The 2016 figure consists of revenues from two Boehringer Ingelheim businesses: Biopharmaceutical contract manufacturing, €613 million ($751.3 million) and “Industrial Customers,” consisting of third-party businesses in pharmaceutical and chemical production and sales of pharma chemicals, €163 million ($199.8 million).
#10. Asahi Kasei Medical (Asahi Kasei)
2017 revenues: ¥134.8 billion ($1.238 billion)
Figure combines revenues for the first three quarters of 2017 (¥103 billion), with fourth-quarter 2016 revenues (¥31.8 billion) for Asahi Kasei Medical, the segment of Asahi Kasei that includes “products for the manufacturing process of biopharmaceuticals and other new drugs” as well as drugs and blood purification devices for chronic and acute renal failure. The company reported October–December 2017 results on February 7.
#9. Sartorius Stedim Biotech
#8. Thermo Fisher Scientific
#7. CPC (Colder Products Co.)
#6. Lonza – Pharma & Biotech
#4. Fujifilm Healthcare (Fujifilm Holdings)
#3. GE Healthcare (General Electric)
#2. Danaher Life Sciences (Danaher)
#1. MilliporeSigma (Merck KGaA)